New hope for hard-to-treat cancers: experimental combo targets STK11 mutation

NCT ID NCT05887492

Ongoing Disease control Sponsor: Tango Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests an experimental drug called TNG260 combined with an immunotherapy (pembrolizumab) in people with advanced solid tumors that have a specific gene change (STK11 mutation). The goal is to find the best dose and see if the combination is safe and can shrink tumors. About 126 adults with advanced lung or other solid tumors will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG ADENOCARCINOMA LUNG CANCER NON-SMALL CELL LUNG CANCER SOLID TUMORS, ADULT

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Florida Cancer Specialists

Sarasota, Florida, 34232, United States
Henry Ford Health System

Detroit, Michigan, 48202, United States
NEXT Oncology Virginia

Fairfax, Virginia, 22031, United States
NYU Langone Hematology Oncology Associates-Mineola

Mineola, New York, 11501, United States
New York University Langone Health

New York, New York, 10016, United States
SCRI at HealthOne

Denver, Colorado, 80218, United States
START MidWest

Grand Rapids, Michigan, 49546, United States
Sarah Cannon Tennessee Oncology

Nashville, Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
UCLA Hematology/Oncology

Santa Monica, California, 90404, United States
US Oncology Investigational Products Center

Dallas, Texas, 75246, United States
US Oncology Investigational Products Center

Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.